期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Peginterferon and ribavirin treatment for hepatitis C virus infection 被引量：16

Peginterferon and ribavirin treatment for hepatitis C virus infection
下载PDF
导出
摘要 Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients. Pegylated interferon α （IFNα） in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus （HCV） infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.
作者 Akihito Tsubota Kiyotaka Fujise Yoshihisa Namiki Norio Tada
机构地区 Institute of Clinical Medicine and Research
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第4期419-432,共14页 世界胃肠病学杂志（英文版）
关键词 Pegylated interferon α RIBAVIRIN Chronic hepatitis C virus infection Difficult-to-treat patient Individualized treatment Response-guided therapy Specifically targeted antiviral therapy for hepatitis C virus 丙型肝炎病毒 治疗药物 聚乙二醇化 病毒感染 利巴韦林 干扰素 修改方案 结合疗法
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献1

二级参考文献11

  • 1Dr. Akihito Tsubota MD,Hiromitsu Kumada MD,Kazuaki Chayama MD,Yasuji Arase MD,Satoshi Saitoh MD,Isao Koida MD,Naoya Murashima MD,Yoshiyuki Suzuki MD,Masahiro Kobayashi MD,Kimiko Takagi BSc,Mariko Kobayashi BSc,Kenji Ikeda MD.Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections[J].Digestive Diseases and Sciences.1996(10)
  • 2Shiffman ML,Suter F,Bacon BR,Nelson D,Harley H,Sola R,Shafran SD,Barange K,Lin A,Soman A,Zeuzem S.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[].The New England Journal of Medicine.2007
  • 3Dalgard O,Bjoro K,Ring-Larsen H,Bjornsson E,Holberg- Petersen M,Skovlund E,Reichard O,Myrvang B,Sundelof B,Ritland S,Hellum K,Fryden A,Florholmen J,Verbaan H.Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response[].Hepatology.2008
  • 4Tsubota A,Kumada H,Chayama K,Arase Y,Saitoh S,Koida I,Murashima N,Suzuki Y,Kobayashi M,Takagi K,Kobayashi M,Ikeda K.Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections[].Digestive Diseases and Sciences.1996
  • 5Lee WM,Reddy KR,Tong MJ,Black M,van Leeuwen DJ,Hollinger FB,Mullen KD,Pimstone N,Albert D,Gardner S.Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group[].Hepatology.1998
  • 6Tabaru A,Narita R,Hiura M,Abe S,Otsuki M.Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a[].The American journal of Gastroenterology.2005
  • 7Jeong S,Kawakami Y,Kitamoto M,Ishihara H,Tsuji K,Aimitsu S,Kawakami H,Uka K,Takaki S,Kodama H,Waki K,Imamura M,Aikata H,Takahashi S,Chayama K.Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy[].Journal of Gastroenterology.2008
  • 8McHutchison JG,Gordon SC,Schiff ER,Shiffman ML,Lee WM,Rustgi VK,Goodman ZD,Ling MH,Cort S,Albrecht JK.Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.Hepatitis Interventional Therapy Group[].The New England Journal of Medicine.1998
  • 9Poynard T,Marcellin P,Lee SS,Niederau C,Minuk GS,Ideo G,Bain V,Heathcote J,Zeuzem S,Trepo C,Albrecht J.Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus International Hepatitis Interventional Therapy Group (IHIT)[].The Lancet.1998
  • 10Hadziyannis SJ,Sette H Jr,Morgan TR,Balan V,Diago M,Marcellin P,Ramadori G,Bodenheimer H Jr,Bernstein D,Rizzetto M,Zeuzem S,Pockros PJ,Lin A,Ackrill AM.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose[].Annals of Internal Medicine.2004

共引文献2

同被引文献87

引证文献16

二级引证文献61

World Journal of Gastroenterology
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部